23:05 , Feb 1, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Fiscal 2Q; (C) During trading hours in Europe; premarket on U.S. exchange Company Date...
01:11 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....
00:51 , Feb 1, 2019 |  BC Week In Review  |  Company News

Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Jan. 29 that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed plans in its 2018 earnings...
00:35 , Feb 1, 2019 |  BC Innovations  |  Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
23:47 , Jan 30, 2019 |  BC Extra  |  Clinical News

Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has...
01:20 , Jan 30, 2019 |  BC Extra  |  Company News

Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Tuesday that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed plans in its 2018 earnings to...
23:50 , Jan 28, 2019 |  BC Extra  |  Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
22:40 , Jan 23, 2019 |  BC Innovations  |  Translation in Brief

Partners in Neglected Infections

Collaborations between two companies and two Liverpool-based institutes have yielded new compounds targeting bacteria in the genus Wolbachia that could treat onchocerciasis and lymphatic filariasis faster and help prevent transmission more effectively than available therapies....
00:52 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: GSK, A*STAR, Moderna

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Philip Hampton will step down as chairman ahead of the pharma’s planned split of its consumer healthcare and innovative R&D businesses. The pharma said it has started to search for...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...